| Today’s Big NewsMay 20, 2025 |
|
Thursday, May 29, 2025 | 11am ET / 8am PT While the use of precision therapies continues to expand, precision oncology drug development is facing increasing costs and complexity. It is more important than ever to implement strategies and solutions for maximizing efficiencies throughout the drug development process. Join us to learn more. 
|
|
| By Zoey Becker FDA Commissioner Marty Makary, M.D., and CBER head Vinay Prasad, M.D., detailed their new approach to COVID vaccines in a Tuesday update. The agency leaders say they're pursuing an "evidence-based approach to COVID-19 vaccination." |
|
|
|
By Nick Paul Taylor Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China rights to a clinical candidate, establishing itself as a challenger to BioNTech, Merck & Co. and Summit Therapeutics in a scorching-hot area of immuno-oncology. |
By Angus Liu Roche looks unlikely to be able to move its DLBCL drug Columvi earlier in the treatment sequence after experts on an FDA advisory committee joined the agency in questioning the regional imbalance of clinical trial data. What's more, both FDA Commissioner Martin Makary, M.D., and longtime FDA oncology chief Richard Pazdur, M.D., have a new message for drug developers. |
By Gabrielle Masson Fierce 15 nominations are open! We're searching for the most innovative, resourceful and visionary biotechs leading the way through the industry's mercurial conditions. |
|
Thursday, June 5, 2025 | 11am ET / 8am PT Off-target binding can be a significant hurdle in the development of antibody-based therapies, with limitations of conventional screening methods being a key factor. Join our webinar to learn more about the latest approaches to specificity profiling. Register now. 
|
|
By Conor Hale The trial will aim to reduce X-ray exposure by 50% over the lowest-available setting on Philips’ Azurion image-guided therapy systems. |
By Gabrielle Masson Schrödinger is laying off 60 staffers, or about 7% of its workforce, in an effort to save cash and boost efficiency. |
By Eric Sagonowsky President Donald Trump's recent Executive Order on drug prices applies to "all brand products across all markets that do not currently have generic or biosimilar competition," the HHS said in a Tuesday press release. |
By Andrea Park Fresh off taking the top spot in an annual survey of how patient groups around the world view major drugmakers, ViiV Healthcare has clinched the No. 1 slot in a U.S.-specific version of the survey, too. |
By James Waldron A dementia-focused transatlantic venture capital initiative has secured $269 million in commitments for its second fund. |
By Kevin Dunleavy As Eli Lilly and Novo Nordisk continue to go in opposite directions in their diabetes and obesity market rivalry, so too have they changed positions in the annual IDEA Pharma Innovation Index. Lilly advanced from fourth place in 2024 to the top spot this year, supplanting 2024 champion Novo. |
By Nick Paul Taylor SK Life Science is encouraging patients beetling down the long and winding road toward seizure-free life to switch gears. In a new nationwide direct-to-consumer ad, the Xcopri manufacturer asks partial-onset seizure patients to consider switching to a new treatment. |
By Conor Hale The trial tested Shockwave Medical's vessel-clearing approach as the primary procedure for women with hardened, calcified blockages in the heart’s coronary arteries. |
By Andrea Park Drugmakers looking to broaden their appeal among healthcare professionals can forgo flashy gimmicks and lavish freebies—what doctors really want, according to a new report, is access to practical, helpful information. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," Fierce Pharma breaks down President Donald Trump’s executive order targeting drug prices and what it could mean for the industry as broader policy shifts unfold. |
|
|---|
|
|
|
Wednesday, June 11, 2025 | 11am ET / 8am PT Join us for a deep dive into the strategies and best practices for maximizing valuation by improving productivity in modern clinical trials. We'll discuss key ways to achieve tangible productivity gains, accelerate timelines, and avoid costly protocol amendments or clinical failures. Register now to learn expert tips for maximizing efficiency and effectiveness. 
|
|
Whitepaper Don’t delay your gene transfer trial’s start-up timeline by gaining the latest insights from WCG’s case study on the power of a seamless Institutional Review Board (IRB) and Institutional Biosafety Committee (IBC) review process. Sponsored by: WCG |
Whitepaper Learn how the SpyLock service can offer fast bispecific generation, reduce workload, and accelerate candidate selection. Sponsored by: Bio-Rad |
Whitepaper We interviewed 24 Medical Affairs leaders on the critical success factors for building a Best Practice Medical Affairs organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
+(2)+(1).png)
